Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A multi-regional clinical trial with participating sites planned in the following countries
pending approval from the applicable oversight authorities:

- Argentina

- Brazil

- Bulgaria

- Canada

- Colombia

- Czech Republic

- Denmark

- France

- Germany

- Hungary

- India

- Israel

- Japan

- Mexico

- Netherlands

- Poland

- Romania

- Russian Federation

- Slovakia

- South Africa

- Spain

- Ukraine

- United Kingdom

- United States

Inclusion Criteria:

1. Fasting TG ≥ 200 mg/dL (2.26 mmol/L) and < 500 mg/dL (5.65 mmol/L) at Visit 1
(Screening/Enrollment Visit) or Visit 1.1 (Retest)

2. HDL-C ≤ 40 mg/dL (1.03 mmol/L) at Visit 1 (Screening/Enrollment Visit) or Visit 1.1
(Retest)

3. Type 2 diabetes of longer than 12 weeks duration documented in medical records, for
example: local laboratory evidence through medical record review of elevated HbA1c (≥
6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥ 126 mg/dL [7.0 mmol/L], 2-hour
≥ 200 mg/dL [11.1 mmol/L] during oral glucose tolerance testing, or random value ≥ 200
mg/dL with classic symptoms, or currently taking medication for treatment of diabetes;
AND either

1. Age ≥ 50 years if male or ≥ 55 years if female (primary prevention cohort); OR

2. Age ≥ 18 years and established systemic atherosclerosis (secondary prevention
cohort), defined as any 1 of the following:

- i. Prior MI or ischemic (non-hemorrhagic) stroke

- ii. Coronary angiographic lesion of ≥ 60% stenosis in a major epicardial
vessel or ≥ 50% left main stenosis

- iii. Asymptomatic carotid disease with ≥ 70% carotid artery stenosis

- iv. Symptomatic carotid disease with ≥ 50% carotid artery stenosis

- v. Symptomatic lower extremity PAD (ie, intermittent claudication, rest
pain, lower extremity ischemic ulceration, or major amputation with either
ankle-brachial index ≤ 0.9 or other diagnostic testing [eg, toe-brachial
index, angiogram, or other imaging study])

- vi. Prior arterial revascularization procedure (including coronary, carotid,
or peripheral angioplasty/stenting, bypass, or atherectomy/endarterectomy)

Exclusion Criteria:

1. Current or planned use of fibrates or agents with PPAR-α agonist activity (eg,
saroglitazar) within 6 weeks (42 days) of Visit 1 (Screening/Enrollment Visit). Note:
PPAR-γ agonists (eg, glizatones such as pioglitazone and rosiglitazone) are allowed

2. Known sensitivity to PPAR-α agonists or tablet excipients

3. Initiation of, or change in, current TG-lowering therapy within 12 weeks of Visit 1
(if applicable). Note: TG-lowering therapy is defined as niacin > 100 mg/day or
dietary supplements or prescription omega-3 fatty acids > 1 g/day

4. Type 1 diabetes mellitus